CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-19 | LEONARD JOHN M President and CEO | Option exercise | +22,682 | $13.40 | $304K | 741,987 |
| 2021-08-19 | LEONARD JOHN M President and CEO | Sale | −9,726 | $150.46 | $1.5M | 732,261 |
| 2021-08-19 | LEONARD JOHN M President and CEO | Sale | −6,993 | $151.56 | $1.1M | 725,268 |
| 2021-08-19 | LEONARD JOHN M President and CEO | Sale | −5,963 | $152.30 | $908K | 719,305 |
| 2021-08-19 | LEONARD JOHN M President and CEO | Option exercise · Stock Option (right to buy) | −22,682 | 251,277 | ||
| 2021-08-09 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +2,400 | $12.62 | $30K | 3,191 |
| 2021-08-09 | Lebwohl David EVP, Chief Medical Officer | Sale | −2,400 | $164.05 | $394K | 791 |
| 2021-08-09 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Stock Option (right to buy) | −2,400 | 197,600 | ||
| 2021-08-05 | Goddard Glenn EVP, Chief Financial Officer | Option exercise | +20,000 | $19.27 | $385K | 20,000 |
| 2021-08-05 | Goddard Glenn EVP, Chief Financial Officer | Sale | −9,902 | $150.65 | $1.5M | 10,098 |
| 2021-08-05 | Goddard Glenn EVP, Chief Financial Officer | Sale | −9,568 | $151.41 | $1.4M | 530 |
| 2021-08-05 | Goddard Glenn EVP, Chief Financial Officer | Sale | −530 | $152.13 | $81K | 0 |
| 2021-08-05 | Goddard Glenn EVP, Chief Financial Officer | Option exercise · Stock Option (right to buy) | −20,000 | 70,000 | ||
| 2021-08-04 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise | +26,000 | $13.40 | $348K | 28,391 |
| 2021-08-04 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −1,471 | $135.47 | $199K | 26,920 |
| 2021-08-04 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −6,814 | $136.79 | $932K | 20,106 |
| 2021-08-04 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −6,344 | $137.72 | $874K | 13,762 |
| 2021-08-04 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −4,419 | $138.78 | $613K | 9,343 |
| 2021-08-04 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −2,772 | $139.85 | $388K | 6,571 |
| 2021-08-04 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −4,054 | $140.73 | $571K | 2,517 |
Page 19 of 40 · 783 trades